DK1701698T3 - Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779 - Google Patents

Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779

Info

Publication number
DK1701698T3
DK1701698T3 DK04814371T DK04814371T DK1701698T3 DK 1701698 T3 DK1701698 T3 DK 1701698T3 DK 04814371 T DK04814371 T DK 04814371T DK 04814371 T DK04814371 T DK 04814371T DK 1701698 T3 DK1701698 T3 DK 1701698T3
Authority
DK
Denmark
Prior art keywords
cci
pharmaceutical composition
oral administration
directly compressible
compressible pharmaceutical
Prior art date
Application number
DK04814371T
Other languages
Danish (da)
English (en)
Inventor
Muhammad Ashraf
Eric J Benjamin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1701698T3 publication Critical patent/DK1701698T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK04814371T 2004-01-08 2004-12-14 Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779 DK1701698T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53495104P 2004-01-08 2004-01-08
PCT/US2004/042178 WO2005070393A2 (en) 2004-01-08 2004-12-14 Directly compressible pharmaceutical composition of the rapamycin ester cci-779

Publications (1)

Publication Number Publication Date
DK1701698T3 true DK1701698T3 (da) 2008-05-05

Family

ID=34806893

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04814371T DK1701698T3 (da) 2004-01-08 2004-12-14 Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779

Country Status (31)

Country Link
US (1) US20050152983A1 (pt)
EP (1) EP1701698B1 (pt)
JP (1) JP2007517879A (pt)
KR (1) KR20060130162A (pt)
CN (1) CN1921861A (pt)
AR (1) AR047180A1 (pt)
AT (1) ATE383859T1 (pt)
AU (1) AU2004314213A1 (pt)
BR (1) BRPI0418373A (pt)
CA (1) CA2552595A1 (pt)
CR (1) CR8491A (pt)
CY (1) CY1107373T1 (pt)
DE (1) DE602004011398T2 (pt)
DK (1) DK1701698T3 (pt)
EC (1) ECSP066757A (pt)
ES (1) ES2298861T3 (pt)
GT (1) GT200500003A (pt)
HK (1) HK1090308A1 (pt)
HN (1) HN2005000005A (pt)
IL (1) IL176519A0 (pt)
MX (1) MXPA06007829A (pt)
NO (1) NO20062930L (pt)
PA (1) PA8621201A1 (pt)
PE (1) PE20050683A1 (pt)
PL (1) PL1701698T3 (pt)
PT (1) PT1701698E (pt)
RU (1) RU2006122517A (pt)
TW (1) TW200526213A (pt)
UA (1) UA84903C2 (pt)
WO (1) WO2005070393A2 (pt)
ZA (1) ZA200605631B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0414066A (pt) 2003-09-03 2006-10-24 Wyeth Corp 42-éster de rapamicina amorfo com ácido 3-hidróxi-2-( hidroximetil )-2-metilproipiÈnico e composições farmacêuticas que o contenha
WO2005105811A1 (en) * 2004-04-14 2005-11-10 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
JP2007534337A (ja) * 2004-04-27 2007-11-29 ワイス ラパマイシン特異的メチラーゼを用いるラパマイシンの標識
CA2596392A1 (en) * 2005-02-15 2006-08-24 Wyeth Orally bioavailable cci-779 tablet formulations
EP1962839A4 (en) 2005-11-14 2010-08-25 Ariad Pharma Inc ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
CA2656019C (en) * 2006-06-28 2016-09-13 Emisphere Technologies, Inc. Gallium nitrate formulations
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
JP2013527223A (ja) 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
EA031737B1 (ru) 2010-06-03 2019-02-28 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы
CA2875986C (en) 2012-06-04 2020-06-09 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2014018567A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
MD3265084T2 (ro) 2015-03-03 2024-05-31 Pharmacyclics Llc Formulări farmaceutice ale inhibitorului tirozin kinazei Bruton
JP6793652B2 (ja) * 2015-09-03 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5928668A (en) * 1993-12-21 1999-07-27 Applied Analytical Industries, Inc. Method for dry blend compression of medicaments
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
ES2252780T3 (es) * 1996-08-22 2006-05-16 Jagotec Ag Composiciones que comprenden microparticulas de sustancias insolubles en agua y metodo para su preparacion.
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
DE60324609D1 (de) * 2002-09-17 2008-12-18 Wyeth Corp GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
WO2005011688A1 (en) * 2003-07-25 2005-02-10 Wyeth Cci-779 lyophilized formulations
WO2005016935A2 (en) * 2003-08-07 2005-02-24 Wyeth Regioselective synthesis of cci-779
BRPI0414066A (pt) * 2003-09-03 2006-10-24 Wyeth Corp 42-éster de rapamicina amorfo com ácido 3-hidróxi-2-( hidroximetil )-2-metilproipiÈnico e composições farmacêuticas que o contenha
US20060142422A1 (en) * 2004-12-07 2006-06-29 Toshikazu Kobayashi Hydrolysis resistant polyester compositions and articles made therefrom
CA2596392A1 (en) * 2005-02-15 2006-08-24 Wyeth Orally bioavailable cci-779 tablet formulations

Also Published As

Publication number Publication date
CY1107373T1 (el) 2012-12-19
BRPI0418373A (pt) 2007-05-22
PE20050683A1 (es) 2005-11-04
HK1090308A1 (en) 2006-12-22
PA8621201A1 (es) 2005-12-23
HN2005000005A (es) 2009-04-17
US20050152983A1 (en) 2005-07-14
CR8491A (es) 2008-08-21
PL1701698T3 (pl) 2008-03-31
JP2007517879A (ja) 2007-07-05
DE602004011398T2 (de) 2009-01-15
AU2004314213A1 (en) 2005-08-04
CA2552595A1 (en) 2005-08-04
ZA200605631B (en) 2010-01-27
ECSP066757A (es) 2006-11-16
DE602004011398D1 (de) 2008-03-06
EP1701698A2 (en) 2006-09-20
WO2005070393A3 (en) 2006-09-28
NO20062930L (no) 2006-10-02
AR047180A1 (es) 2006-01-11
KR20060130162A (ko) 2006-12-18
ES2298861T3 (es) 2008-05-16
MXPA06007829A (es) 2006-09-01
ATE383859T1 (de) 2008-02-15
EP1701698B1 (en) 2008-01-16
TW200526213A (en) 2005-08-16
RU2006122517A (ru) 2008-02-20
UA84903C2 (ru) 2008-12-10
GT200500003A (es) 2005-08-18
IL176519A0 (en) 2006-10-05
WO2005070393A2 (en) 2005-08-04
CN1921861A (zh) 2007-02-28
PT1701698E (pt) 2008-03-27

Similar Documents

Publication Publication Date Title
DK1701698T3 (da) Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779
DK2172205T3 (da) Farmaceutisk formulering bestående af lanthan-forbindelser
DK2058020T3 (da) Indretning til indgivelse af lægemiddel
BRPI0511900A (pt) composições farmacêuticas
DK2361609T3 (da) Formulering af småmolekylære lægemidler med forsinket frigivelse
DK1928405T3 (da) Farmaceutiske sammensætninger til behandling af indre øreforstyrrelser
DK1656347T3 (da) Substituerede indolderivater til farmaceutisk sammensætning til behandling af luftvejssygdomme
DK2292219T3 (da) Transdermalt terapeutisk system til administration af rivastigmin
DK2158905T3 (da) Sammensætning til transdermal administration af fentanyl
DK3072507T3 (da) Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
DK1983964T3 (da) Anordning til indgivelse af lægemiddel
DK1725218T3 (da) Farmaceutisk sammensætning omfattende pimobendan
NO20053119D0 (no) Farmasoytiske sarmmensetninger med fentanyl for intranasal administrasjon.
DK1601359T3 (da) Væskeformige, farmaceutiske formuleringer af palonosetron
DK1837019T3 (da) Orale dispergerbare farmaceutiske sammensætninger
DE60317803D1 (de) Pharmazeutische zusammensetzungen enthaltend cyclosporin zur oralen verabreichung
DK1587478T3 (da) Farmaceutisk sammensætning
BRPI0716698A2 (pt) Composto, composição farmacêutica e uso de um composto
DK1798234T3 (da) Farmaceutisk sammensætning omfattende temozolomidester
DK1617827T3 (da) Farmaceutisk sammensætning i form af en hydrogel til den transdermale administration af aktivstoffer
DK1474114T3 (da) Oral doseringsform til reguleret frigivelse af et lægemiddel
DK1691808T3 (da) Farmeceutisk sammensætning til oral indgivelse af et pyrazol-3-carboxamid
ITMI20061741A1 (it) Composizioni farmaceutiche per la somministrazione orale di sostanze proteiche
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina
DE602005005033D1 (de) Sprühgetrocknete pharmazeutische zusammensetzungen